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Abstract 
The eye is a highly specialised organ that is subject to a huge range of pathology. Both local 
and systemic disease may affect different anatomical regions of the eye. The least invasive 
routes for ocular drug administration are topical (e.g. eyedrops) and systemic (e.g. tablets) 
formulations. Barriers that subserve as protection against pathogen entry also restrict drug 
permeation. Topically administered drugs often display limited bioavailability due to many 
physical and biochemical barriers including the pre-corneal tear film, the structure and 
biophysiologic properties of the cornea, the limited volume that can be accommodated by 
the cul-de-sac, the lacrimal drainage system and reflex tearing. The tissue layers of cornea 
and conjunctiva are further key restrictors to drug delivery. Using carriers that enhance 
viscosity or bind to the ocular surface increase bioavailability. Matching the pH and polarity 
of drug molecules to the tissue layers allows greater penetration. Drug delivery to the 
posterior segment is a greater challenge and currently the standard route is via intravitreal 
(IVT) injection, notwithstanding the risks of endophthalmitis and retinal detachment with 
frequent injections. Intraocular implants that allow sustained drug release are at different 
stages of development. Novel exciting therapeutic approaches include methods for 
promoting transscleral delivery, sustained release devices, nanotechnology and gene 
therapy.   
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Abbreviations 
AADS Airless Antibacterial Dispensing System 
AAV Adeno-associated-virus 
ADAs Anti-drug antibodies 
AIDS Acquired immune deficiency syndrome 
AMD Age-related macular degeneration 
BAC Benzalkonium chloride 
BRB Blood retinal barrier 
BRVO Branch retinal vein occlusion 
CMV Cytomegalovirus 
CNTF Ciliary neutrophic factor 
CNV Choroidal neovascularisation 
CRVO Central retinal vein occlusion 
DALYs Disability-adjusted life-years 
DR Diabetic retinopathy 
ECM Extracellular matrix 
ESC Embryonic stem cells 
EVA Ethylene vinyl acetate 
FA Fluocinolone acetonide 
Fab Fragment antigen-binding 
FDA Food and Drug Administration 
GA Geographic atrophy 
GAGs Glycosaminoglycans 
GFS Glaucoma filtration surgery 
HA Hyaluronic acid 
HAART Highly active antiretroviral therapy 
HPMC Hydroxypropylmethylcellulose 
hPSCs Human pluripotent stem cells 
IL-6 Interleukin-6 
IOP Intraocular pressure 
iPSCs Induced pluripotent stem cells 
IVT Intravitreal 
MEMS Microelectromechanical system 
MW Molecular weight 
PAMAM Poly amidoamine 
PDGF Platelet-derived growth factor 
PDS Port delivery system 
PEGDA Poly(ethylene glycol) diacrylate 
PET Polyethylene terephthalate 
PLGA Poly(lactic–co-glycolic acid 
PMMA Poly(methyl methacrylate) 
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pNIPAAM Poly(N-isopropylacrylamide) 
PVA Polyvinyl alcohol 
rAAV Recombinant adeno-associated virus 
RP Retinitis pigmentosa 
RPE Retinal pigment epithelium 
RVO Retinal vein occlusion 
TA Triamcinolone acetonide 
VEGF Vascular endothelial growth factor 
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Introduction 
Vision is often considered as the most important of senses, and the one that most people 
fear losing. Vision is often thought to be the key enabling sense for a person to work and 
function independently. Considerable efforts to combat vision loss continue to be made as 
blinding ocular diseases are more prevalent with an increasingly ageing population. All 
measurements for quality of life, such as disability-adjusted life-years (DALYs), confirm that 
visual impairment is a highly ranked burden in all countries (Chiang et al. 2006). The leading 
causes of vision impairment and irreversible blindness are posterior segment related 
diseases (Pascolini & Mariotti 2012), which include glaucoma, age-related macular 
degeneration (AMD), macular oedema secondary to retinal vein occlusion (RVO), 
cytomegalovirus (CMV) retinitis, posterior uveitis, diabetic retinopathy (DR), and retinitis 
pigmentosa (Thrimawithana et al. 2011; del Amo et al. 2015; Waite et al. 2017).  
Glaucoma is a term used to describe a group of conditions with an optic neuropathy, 
characteristic morphological changes in the optic nerve head and visual field defects. It 
remains a leading cause of irreversible blindness throughout the world and one of the most 
common neuropathies. It is estimated that 60.5 million people suffered from it in 2010 and 7 
million believed to be bilaterally blind (Quigley & Broman 2006). The number of people with 
glaucoma is projected to increase to 111.8 million in 2040 (Tham et al. 2014). Over the last 
century, in fact, the proportion of blindness attributed to glaucoma in developed countries 
has changed very little (10%) (Taylor 2009). In developed countries the main cause of 
blindness 100 years ago was corneal disease, fifty years ago it was cataract and in the 
present day it is AMD. No reduction in the proportion of blindness due to glaucoma is not 
simply because there have been no advances in treatment. A major factor is the ageing 
population. As a population becomes healthier and people live longer, the incidence of this 
degenerative optic neuropathy that reaches a clinically detectable threshold will increase. 
The mainstay of treatments involves trying to slow the optic nerve degeneration. The biggest 
risk factor for accelerated progression is an increased level of intraocular pressure (IOP) and 
reducing this is the only proven therapy in everyday use. 
This article is protected by copyright. All rights reserved. 
AMD affects approximately 10 million people worldwide and is one of the leading 
causes of vision loss in elderly patients over 60 years of age. The prevalence of AMD 
accounts for 20% of all posterior segment disorders in the 65-74 years age group and 35% 
in older age groups (Edelhauser et al. 2010) and is predicted to affect 288 million people by 
2040 (del Amo et al. 2017). Cataract, DR, glaucoma and AMD will increase to nearly 70 
million adults by 2050 (Joseph & Venkatraman 2017). Loss of vision will increase with the 
increase in the ageing population, which in turn will pose a challenge for the human health 
and economic growth (Delplace et al. 2015). 
Inflammatory, angiogenic and fibrotic processes cause tissue damage and vision 
loss. These processes are also major contributors to the failure of current treatments for 
these diseases. Increased knowledge of the molecular mechanisms of blinding diseases (de 
Oliveira Dias et al. 2011; Rodrigues et al. 2009) has driven the development of therapeutic 
proteins including antibody-based medicines (Penedones et al. 2014). Vascular endothelial 
growth factor (VEGF) neutralising antibodies have considerably improved the treatment of 
exudative macular degeneration (wet AMD) and DR. A major challenge during both 
preclinical and clinical development is to determine the ocular clearance rates of new 
medicines. Even though the anti-VEGF antibody based medicines can be administered once 
a month and in some cases every other month (Stewart et al. 2012), much research is 
focused on developing medicines that will require less frequent dosing regimens.  
Another factor in the development of longer acting formulations is the cost of the 
drugs and overall treatment costs, which is a function of dosing frequency. The expenditure 
to treat blinding ophthalmic diseases is considerable, with $ 51.4 billion spent in the US 
alone each year (2007). For example, ranibizumab (licensed) and bevacizumab (unlicensed) 
are widely used to treat AMD. Each injection of ranibizumab (Lucentis®) can cost $ 2,000, 
whereas bevacizumab (Avastin®) can cost only $ 50 for each intravitreal (IVT) dose (Raftery 
et al. 2007). Two multi-center randomised controlled clinical trials (IVAN and CATT) 
compared the use of ranibizumab and bevacizumab (Ahfat & Zaidi 2013; Chakravarthy et al. 
2012; Martin et al. 2012). No difference was found in visual acuity outcome during 1- and 2-
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year treatment periods respectively (Chakravarthy et al. 2012; Martin et al. 2012). 
Bevacizumab is normally provided as a solution in a glass vial containing 400 mg of the 
antibody at a concentration of 25 mg/mL. For ocular use, bevacizumab is often transferred 
under aseptic conditions into ready-to-use syringes for IVT injection by compounding 
pharmacies for local distribution. Many health systems cannot cope with the increasing 
demands for IVT injection, so bevacizumab is widely used (Elshout et al. 2014; Kwong & 
Mohamed 2014). 
 
The eye-a complex organ 
The anatomy of the eye and complex physiology of the retina means that the development of 
efficacious medicines is challenging. The eye is a specialised organ that enables light to be 
focused and processed into nerve impulses for interpretation by our brain. A huge range of 
pathology affects the eye, with either local triggers or manifestations of systemic disease 
such as diabetes mellitus. Furthermore, different parts of the eye can be affected to different 
degrees, with implications for drug delivery. The eye is broadly divided into two 
compartments called the anterior (front of the eye) and posterior (back of the eye) segment. 
Contact lens related infections occur in the cornea of the anterior segment, whereas macular 
degeneration is in the central retina of the posterior segment. Endophthalmitis, (infection 
within the eye) can cause blindness within a matter of hours. Optic nerve degeneration in 
open angle glaucoma may take many years before patients are aware that vision is 
compromised. 
The least invasive routes for ocular drug administration are topical (e.g. eye drops) 
and systemic (e.g. tablets) formulations. The superficial nature of the eye enables local 
administration (usually eye drops), the main modality of treatment for anterior segment 
disease. One advantage of this is to bypass the liver, thus avoiding the need for higher 
systemic doses required with the oral route. The efficacy of drugs may also be assessed at a 
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local level. Parameters can be measured directly, for example the IOP in glaucoma, or 
through visual interpretation for signs of oedema in exudative macular degeneration. 
Local applications do pose some disadvantages. Most treatments are self-
administered and rely on a compliant patient, but many patients take their medication 
sporadically. This can be demonstrated by attaching detectors to bottles during glaucoma 
treatment used by patients (Kass et al. 1986). The reported rate of application from patients 
differed significantly to the measured rate (Kass et al. 1986). Consequently, even if drug 
delivery is optimised, efficacy may not be achieved. Topically administered drugs often 
display limited bioavailability (< 5%) due to many physical and biochemical barriers including 
the pre-corneal tear film, the structure and biophysiologic properties of the cornea, the 
limited volume that can be accommodated by the cul-de-sac, the lacrimal drainage system, 
reflex tearing and the aqueous outflow within the eye (Ranta & Urtti 2006; Peyman & 
Ganiban 1995; Rodríguez Villanueva et al. 2016). Newer methods of drug delivery include 
sustained release preparations that allow reduced frequency of drug administration 
(Rodríguez Villanueva et al. 2016; Mehta et al. 2017). Preservative free eye drops can be 
achieved with a new multidose bottle with an Airless Antibacterial Dispensing System 
(AADS, Pfizer Inc, USA) containing a valve system and an airless pump with a silver 
antibacterial coil (Ghate & Edelhauser 2008).  
The patient population is also often elderly and susceptible to side effects. Despite 
lower doses needed than oral drugs, systemic toxicity can still be an issue. An elderly patient 
tends to have a lower body mass index, as well as decreased renal function. Furthermore, 
these patients are more likely to be on multiple medications that may interact. Even small 
quantities of drug absorbed systemically may have side effects, such as an increase in falls 
with topical β-blocker use (Glynn et al. 1991). Another example is the use of atropine. A 50 
μL drop of 1% atropine contains 0.5 mg of drug. Treating both eyes with one dose (1.0 mg) 
can cause a tachycardia (Morton & Thomas 1958). 
Significant ocular barriers that exist to prevent pathogen access also hinder drug 
delivery (Yellepeddi & Palakurthi 2016; Novack & Robin 2016). Transparency is necessary 
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for optical function, and therefore most of the inside of the eye lacks blood vessels. This is at 
the expense, however, of the host defence, which is weaker compared to rest of body, and if 
the barriers are breached, as in endophthalmitis, there are devastating effects. These 
barriers however are also key restrictors to delivering a drug to the area of need. Blinking 
and tear film turnover, designed to wash away foreign material and maintain a smooth clear 
anterior surface, also limits the residence time of a drug. Access to the deeper structures of 
the eye is hindered by a closely packed corneal epithelium and stroma with varying 
lipophilicity. 
Delivery of a drug to the posterior segment has its own particular challenges. The 
vascular conjunctiva, sclera and choroid affect delivery, notwithstanding the tight junctions of 
the blood aqueous barrier of the non-pigmented ciliary body epithelium, and the endothelium 
of blood vessels that constitute the blood retina barrier (BRB). The BRB controls fluid and 
molecular movement between the ocular vascular beds and prevents leakage of 
macromolecules and harmful molecules into the retina (Kaur et al., 2008). Due to the outer 
and inner BRB, the influx of drug into the retina and vitreous regions is limited, requiring the 
systemic administration of high doses to achieve therapeutic concentrations within the eye. 
As a result, drug is distributed and accumulated in all tissues in the body, causing unwanted 
side effects (Myles, et al., 2005). IVT injections are therefore required to administer drugs 
directly to the posterior segment to achieve reproducible and high doses. Although IVT 
injections are required to treat blinding conditions at the back of the eye, repeated 
administration poses potential complications including endophthalmitis, retinal detachment, 
traumatic cataract, intraocular hemorrhage and ocular infections (Jager et al., 2004). 
Particulate contaminants that may be present in a formulation also increases the potential for 
harmful effects to the posterior segment (Jager et al. 2004). In addition, only a little is known 
about vitreous dynamics, partly due to the changes in consistency and anatomy with age 
(Awwad et al., 2015; Bishop et al., 2004; Laude et al., 2010).  
Understanding the nature of ocular barriers, and developing methods of bypassing or 
utilising them together with knowledge of the fluid dynamics within the eye are keys to 
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establishing successful ophthalmic pharmacotherapy. Experimental models act as platforms 
for drug development (Awwad, et al., 2017; Awwad et al., 2015) and translation to the clinic. 
This review aims to examine these barriers, ways of negotiating them, and methods of 
pharmacotherapy employed for different types of drugs. As the pathology and pharmacology 
differs anatomically we aim to discuss separately the anterior and posterior segment, and 
look at some of the future strategies of drug development on the horizon.  
Anterior segment 
Barriers 
The anterior segment of the eye consists of the cornea, conjunctiva, iris, ciliary body and the 
lens. The common chronic anterior segment diseases are cataract, glaucoma and uveitis, 
with cataract accounting for 51% blindness (according on a 2010 survey (Joseph & 
Venkatraman 2017; Pascolini & Mariotti 2012)). The vast majority of pharmacotherapy is 
through topical application by the patients themselves, although other routes such as 
subconjunctival injection are also used. Tear film turnover is the main factor that limits topical 
drug residence time. Human tear volume is approximately 7 µL (Gaudana, et al. 2010). The 
volume of an eye drop of drug is up to 50 µL, and although the cul-de-sac may briefly 
expand to 30 µL (Nagataki & Mishima 1980; Gaudana, Ananthula, Parenky & Ashim K Mitra 
2010), most drug is cleared by nasolacrimal drainage, and then to the systemic circulation 
directly after instillation. Increasing the drop size will therefore not deliver a greater amount 
of drug to the eye, but instead increase the chances of systemic side effects. The optimal 
size of drop to prevent systemic overflow is zero, which is obviously not achievable. 
Droppers have been created that consistently produce smaller volumes (Van Santvliet & 
Ludwig 2004; Kumar et al. 2011). Simpler strategies include nasolacrimal occlusion or 
closing the eyelid. 
Lacrimation caused by irritant drugs, certain excipients, and pH deviation increase 
tear turnover and drug loss. Increase in tonicity can also have significant implications for 
increase in tearing. The normal tear turnover in human is 16%/min (Mishima et al., 1966). 
This article is protected by copyright. All rights reserved. 
Increased lacrimation due to drop instillation results in turnover being increased up to 
80%/min. Therefore, the half-life of a drug is only 4 minutes even with a normal turnover. 
Blinking also increases drainage as eyelid muscle contraction encourages tear flow down 
the nasolacrimal duct. A significant increase in the drug residence time can be achieved 
simply by asking patients to close their eyes after drop instillation and apply pressure 
nasolacrimal duct (Flach 2008). 
The tear film itself traditionally used to be thought of as a simple tri-layer structure, 
consisting of an oily surface layer that reduced evaporative loss, an aqueous middle layer 
that contained enzymes and other anti-bacterials (such as lactoferrin) and a mucin layer that 
provides lubrication and protection of the corneal surface. More recently that view has 
altered with the discovery of numerous glycosaminoglycans (GAGs), mucopolysaccharides 
and other molecules responsible for tear film integrity (Tiffany 2008). Furthermore, the tear 
film is dynamic as fluids are ‘reshuffled’ with blinking (Cher 2012). An unstable tear film is a 
result of dry eye syndrome and chronic eye irritation with changes in the level of lipid, protein 
and mucin profiles (Yellepeddi & Palakurthi 2016). 
Understanding the tear film constituents and dynamics has led to the development of 
methods that increase drug residence time and bioavailability. Inserts provide sustained 
release of drug. Emulsions enable an increased drug load that may not be achievable in 
solution. Vehicles or ointments increase viscosity. Carriers of drug exist that bind to the tear 
film or ocular surface with greater adhesion than drug alone. 
Bacterial ulceration of the cornea is a significant risk factor in people who regularly 
wear contact lenses. Poor hygiene combined and overnight use increases the risk of a 
bacterial infection (Stapleton et al. 2008). Aggressive dosing is required in the initial stages 
of therapy, with hourly or even half hourly drops to prevent ocular spread and loss of the 
eye. It is not uncommon for patients to be admitted to hospital for both day and night 
treatment (Teo et al. 2011). Ocular inserts (Table 1) are solid implants that sit in the cul-de-
sac of the eyelids and slowly dissolve, releasing drug over a long period of time. The 
concept is constantly being explored and reported in literature (Saettone et al. 1994; Kumari 
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et al. 2010; Aburahma & Mahmoud 2011; Franca et al. 2014; Everaert et al. 2017; Rathod et 
al. 2017; Sharma et al. 2017). Pilocarpine, an IOP lowering treatment, was one of the first 
drugs to be formulated as an insert (Ocusert) (Langer 1983). Ocusert is a cul-de-sac 
sustained release insert composed of two membranes of ethylene vinyl acetate (EVA) 
copolymer surrounding a reservoir of pilocarpine allowing drug diffusion (40 μg/hour) for over 
a period of a week for the treatment of glaucoma (Barar et al. 2016; Peyman & Hosseini 
2011; del Amo & Urtti 2008). An ocular insert that combined ciprofloxacin with sodium 
carboxymethylcellulose and polyvinyl alcohol (PVA) has shown significant promise. In vitro 
studies have shown that this insert can maintain levels within a therapeutic range for up to 
48 hours (D. Jain et al., 2010). Good tissue compatibility has also been demonstrated in an 
in vivo rabbit model. Ocular inserts have also been clinically tested for patients with dry eye 
symptoms, with release of hydroxypropyl cellulose alleviating foreign body sensation 
significantly with blurring of vision being the most common side effect (in 8.7% patients) 
(Koffler et al., 2010). 
Suspensions are commonly used to enable application of poorly water-soluble drugs 
such as the steroid prednisolone acetate. The suspension requires shaking to disperse drug 
particles in the bottle. However, drug distribution is still not uniform. Oil-in-water (o/w) 
emulsions are prepared to dissolve the drug in an oil phase and disperse it in the aqueous 
phase with a surfactant, which has been found to improve consistency (Koffler et al. 2010). 
Microemulsions, which are emulsions that are thermodynamically stable and form 
spontaneously, have also shown promise. A low concentration of surfactant maintains the 
drug suspension stability and may enhance penetrance by interacting with the corneal 
epithelial cells (Fialho & da Silva-Cunha 2004). A recent study found that a microemulsion of 
dexamethasone had an improved anti-inflammatory effect in a rabbit uveitic model compared 
to a marketed formulation of dexamethasone (Kesavan et al., 2012).  
An alternative to formulating an emulsion for poorly water-soluble drugs is to combine 
it with a cyclodextrin (Kurkov & Loftsson 2013). Cyclodextrins are oligosaccharides 
consisting of a hydrophilic outer surface and a hydrophobic core (Loftsson & Stefansson, 
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1997). They are able to form inclusion complexes with ‘guest’ drug molecules, which sit 
within the core and the hydrophilic outside aids aqueous solubility. A dynamic equilibrium 
exists between the cyclodextrin drug complex and disassociated drug, enabling drug release 
(Kek et al. 2010). Cyclodextrins have been used preclinically to formulate eye drops 
(Loftsson & Brewster, 2011) with various drugs (Bary et al., 2000; Bozkir et al., 2012; 
Cappello et al., 2001; Jóhannsdóttir et al., 2015; Loftsson et al., 2012; Okamoto et al., 2010; 
Rodriguez-Aller et al., 2015; Siefert & Keipert, 1997). Several cyclodextrin based eye drops 
have been evaluated clinically, e.g. latanoprost and dexamethasone (Tanito et al. 2011; 
Gonzalez et al. 2007; Krag & Hessellund 2014; Shulman et al. 2015), while others have 
been registered in Europe for clinical use, e.g. chromaphenicol (Clorocil®), diclofenac 
(Voltaren Ophthalmic®) and indomethacin (Indocid®) (Davis & Brewster 2004). The 
percentage of cyclodextrin used for drug solubilisation was between 10-30% w/v for most of 
these formulations (Kearse et al., 2001). 
Increasing the viscosity with a carrier increases residence time and in theory the drug 
bioavailability (Bourlais 1995). Ointments are often made from mineral oil, which can pose a 
challenge for the formulation of water-based treatments. The oily base may impair drug 
dissolution, reducing therapeutic efficacy (McCarthy 1975). The oil itself also interferes with 
tear film clarity, leading patients to complain of blurry vision or eyelashes being stuck 
together. Ointments still have an important therapeutic role in the setting of corneal exposure 
or thermal burns, where production of tear film constituents has been disrupted or where the 
ocular surface is damaged (Fish & Davidson 2010).  
Another method of increasing the viscosity with less tear film disruption is to use a 
mucoadhesive component (polymer or excipient) such as polycarbophil (Agrahari et al. 
2016) or carboxymethylcellulose (Reddy & Kim 2011). These substances are long chain 
polymers that bind to the mucous layer constituents on the ocular surface. Amongst the 
salts, lipids and proteins are numerous glycoproteins, such as mucin, that have charged 
carbohydrate groups and end in sialic acid groups. The polymer chains of mucoadhesives, 
which consist of both polar and non-polar groups, swell on contact with water, become 
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entangled and adhere to the mucin molecules (Khutoryanskiy 2010). The polymer length and 
the pH affect drug residence time and bioavailability. A longer chain polymer will have more 
viscosity, entanglement and greater adhesiveness to a certain extent. It will also restrict the 
ability to swell and result in less adhesion. Furthermore, there may be an increase in 
irritation and lacrimation. The pH is also important in determining how strongly a polymer 
binds as it governs whether hydrogen bond formation is able to take place (Grabovac et al., 
2005). For many polymers, a more acidic pH results in greater hydrogen bonding between 
polymer and the mucin on the surface.  
Hyaluronic acid (HA) has the additional property of shear thinning unlike other 
mucoadhesive polymers. With movement, the viscosity of HA decreases. Therefore, with 
blinking the polymer rearranges, but with an eye that is open there is greater stability (Rah 
2011). HA is commonly used for maintaining anterior chamber volume during intraocular 
surgery and for the treatment of dry eye. Its potential for enhancing ocular delivery is still 
being evaluated, though has shown promise with drugs such as pilocarpine (Pahuja et al., 
2012). HA stabilises and organises the extracellular matrix (ECM), regulates cell adhesion 
and motility and mediates cell proliferation and differentiation (Shu et al. 2004; Guter & 
Breunig 2017). The commercially available form, sodium hyaluronate is widely used in 
biomedical applications such as a scaffold material for wound healing and tissue engineering 
due to its biocompatible and biodegradable properties (Ha et al. 2006; Baino 2011). 
 
Routes of drug absorption 
From the tear film there are two main routes of drug absorption to the anterior segment: 
i) The corneal route. The drug passes through the structural layers of the cornea to 
reach the anterior chamber, including the corneal epithelium, stroma, and 
endothelium. 
ii) The non-corneal route. Drugs pass through the conjunctiva, Tenon’s tissue, and 
sclera to reach the anterior chamber. 
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Corneal route 
The cornea consists of three major layers with differential permeability to drug molecules. 
The epithelium and endothelium both consist of cells linked by tight junctions, which restrict 
the passage of large molecules, while the stroma is made up of closely packed collagen. It is 
the epithelium however that provides the most resistance to solute diffusion. Its influence on 
restricting large molecules may be demonstrated by comparing absorption of 14C-
dexamethasone with the epithelium intact to when it is debrided in an animal model (Cox et 
al. 1972a; Cox et al. 1972b) Only after epithelial debridement is 14C-dexamethasone 
detected in the anterior chamber of rabbits after topical administration. Intercellular spaces 
with pore sizes of 60 A allow the passage of small ionic and hydrophilic molecules (<350 Da) 
via the paracellular route (Lee 1990). The transcellular route is the main mechanism of 
absorption of ocular drugs and other larger lipophilic molecules. 
The lipophilicity of the cornea varies with the different layers. The epithelium and 
endothelium are relatively hydrophobic, whereas the corneal stroma is hydrophilic. 
Consequently, there is a parabolic relationship between the corneal permeability and the 
diffusion coefficient (Yoshida & Topliss 1996). With the stroma playing a lesser role in 
resistance, corneal penetrance increases with hydrophobicity with a decrease in penetrance 
in only the most hydrophobic of compounds. In conjunction with lipophilicity, pH is another 
key factor in determining the permeability of the cornea to a drug (Pahuja et al. 2012) There 
is a delicate balance therefore between aiming for a pH appropriate for corneal penetration 
and the physiological pH (7.4), which will result in the least tearing. 
Certain drugs harness the differing lipophilicity of the cornea to their advantage for 
drug delivery. Latanoprost is one of the most common ocular drugs used for the treatment of 
glaucoma, a disease in which there is accelerated optic nerve degeneration in association 
with a raised IOP (Digiuni et al. 2012; Pek et al. 2016). Latanoprost is a prostaglandin 
analogue that reduces IOP by increasing the uveoscleral outflow, through targeting 
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receptors near the drainage angle. Although not fully understood, it is believed that it may 
cause ciliary muscle relaxation, or remodelling of the tissue matrix within the ciliary muscle.  
Latanoprost is formulated as a lipophilic pro-drug ester, which is absorbed easily into 
the corneal epithelium. It is activated by esterases within the epithelium to the active 
hydrophilic moiety and passes through into the anterior chamber. The cornea therefore acts 
as a depot for the pro-drug with prolonged release after a single application. The elimination 
half-life in rabbit corneas has been found to be over an hour (Sjöquist et al. 1998). In 
humans IOP lowering begins between 2-4 hours after application, with the peak effect 
reached between 8-12 hours (Digiuni et al. 2012). This effectively means a once per day 
treatment, which helps with patient compliance. 
The non-corneal route 
Less is known about the permeability of the conjunctiva, Tenon’s, and sclera, and the 
associated pharmacokinetics. Most papers that examine these different tissues report that 
the conjunctiva is more permeable to hydrophilic molecules than the cornea, though it is not 
clear that it is less permeable to hydrophobic molecules. Using a hollow glass cylinder fixed 
to the corneal surface to isolate cornea versus conjunctiva tissue Ahmed and Patton found 
the hydrophilic molecule inulin penetrated conjunctiva and sclera more easily than the 
cornea (Ahmed & Patton 1985).  
Other conjunctival properties that increase drug absorption include a greater surface 
area (17 times that of the cornea in humans (Watsky et al. 1988)), and a larger pore size 
with greater permeability than the cornea (Lawrence & Miller 2004). However, factors that 
reduce absorption include mucous produced by goblet cells, and the presence of lymphatics 
and vasculature that enhance systemic loss of drug. 
Changing the epithelium permeability directly may increase drug penetration. 
Surfactants are ionised substances, which can disrupt the plasma membrane of the 
epithelium. One surfactant in common use is the preservative benzalkonium chloride (BAC). 
Its ability to kill bacteria and prolong the shelf life of medicines makes it the preservative of 
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choice in many preparations. BAC can cause membrane disruption and emulsification of the 
lipid layer of the tear film, where the delivery of drug through the corneal layers may be 
significantly enhanced. This can be seen in studies with acyclovir ointment, a common 
treatment for herpes simplex keratitis. Acyclovir penetrance in ex vivo corneas of rabbits was 
increased by 3 times with a 0.005% BAC solution and by 10 times with a 0.01% BAC 
solution (Majumdar et al. 2008). A standard formulation is between 0.004 and 0.02%. 
However the effects of BAC are toxic that even at low concentrations the presence of BAC 
can cause cell death. A concentration of 0.0001% is sufficient to cause apoptosis. Higher 
concentrations cause necrosis. It is no surprise that patients complain of ocular surface 
irritation when using treatments that contain BAC. Ensuring ocular medications are 
pathogen-free is a mandatory part of formulating an ophthalmic preparation and much 
research has been performed to find other preservatives that have effective bactericidal 
properties but without the toxicity seen with BAC. 
Iontophoresis is the application of electrical current to drive ionised substances into 
tissue (del Amo & Urtti 2008). It is a method of enhancing ocular drug delivery that has been 
in and out of vogue over many years since Wirtz reported its use for the treatment of 
infective corneal ulcers with zinc salts in 1908 (Wirtz 1908). The apparatus usually consists 
of a reservoir of drug connected to an electrode with the other electrode attached to the 
patient. It has been used with some success to enhance delivery of antibiotics such as 
gentamicin, steroids and antiviral treatments both through the cornea and sclera. Side 
effects such as tissue necrosis and patient discomfort have precluded its widespread use, 
however in some circumstances it may have a useful role (Güngör et al. 2010). Recent 
phase I/II trials have shown promise in the treatment of dry eye and uveitis (Patane et al. 
2011; Cohen et al. 2012; Kang-Mieler et al. 2014), 
Periocular injections 
Drugs that are injected underneath the conjunctiva or Tenon’s tissue effectively bypass the 
superficial tear film and conjunctival barriers. Another advantage of this route is the ability to 
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leave a depot of drug within the potential space between tissue layers. Furthermore, more 
posterior placement of the drug enables delivery to the posterior segment (discussed below). 
Periocular injections (Ghate et al. 2007) are particularly pertinent for drugs poorly soluble in 
water such as steroids. Sub-conjunctival, sub-Tenon’s, peri-bulbar injections are commonly 
used in ophthalmology practice. Sub-conjunctival steroid is used for the treatment of 
refractory anterior uveitis. Injections of the antifibrotic agents 5-flurouracil and mitomycin C 
are also applied using this route to prevent scarring after trabeculectomy surgery. Sub-
Tenon’s and peribulbar injections are often the choice method of administering local 
anaesthetic. Less commonly used is the retrobulbar injection, which is associated with the 
small, albeit life-threatening risk of brain stem anaesthesia.  
Posterior segment  
The posterior segment of the eye refers to the posterior two-thirds of the eye, including the 
anterior hyaloid membrane and all the structures behind it such as the vitreous, retina 
choroid and optic nerve. The leading causes of vision impairment and irreversible blindness 
are posterior segment related diseases (Thrimawithana et al. 2011). Inflammation and 
fibrosis are also symptoms associated with posterior segment disorders and ocular tissue 
damage. The uniqueness of the cellular composition and anatomical structure of the retina 
means these biological processes are devastating and detrimental to vision. Inflammatory 
responses or hypoxic stimuli cause abnormal blood vessels to leak resulting in retinal 
thickening and edema, fibrovascular proliferation and fractional retinal detachment. To 
preserve the retinal structure and function, it is crucial to prevent primary vascular 
abnormality (Friedlander 2007). 
Only a decade ago ocular treatments for these diseases were limited and were, at 
best, kept in check with laser therapy. With the advent of anti-VEGF treatment there have 
been significant improvements in stabilising, and sometimes improving disease states and 
vision (Jain et al. 2012). The delivery of anti-VEGF medicines to the posterior segment 
poses a particular challenge. The structures in the anterior segment serve as additional 
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barriers to those discussed above. Furthermore, the direction of aqueous flow in the eye 
(ciliary body to anterior chamber angle) is against the direction of drug delivery via a topical 
route. It is estimated that drugs applied in a conventional topical way are diluted by a factor 
of between 250000 and 1000000 by the time the vitreous is reached (Maurice, 2002).  
Instead the only modalities of treatment in everyday use are either periocular or IVT 
injections. Avoiding all barriers, the IVT route results in the greatest bioavailability, and for 
large molecules, such as proteins, is the only route in current clinical practice. However, 
each time an injection is performed there is a small but significant risk of a blinding 
complication. The risks of retinal detachment and infective endophthalmitis have been 
reported as 0.9% and 0.2% per injection respectively (Jager et al. 2004). Frequent (4-8 
weeks) anti-VEGF treatment will result in a cumulative increase. Much research has been 
performed to improve transscleral delivery (Amrite et al. 2008), which would negate the need 
to breach the walls of the eye and to develop sustained release preparations, which would 
reduce the frequency of repeated IVT injections. 
Periocular barriers 
A drug must penetrate the tissue layers of the globe to reach the back of the eye at a 
therapeutic level. Various tissue barriers have varying tissue permeability. Unlike the cornea 
however, there is blood flow through the periocular tissues, and considerable drug is lost to 
the systemic circulation via venules and lymphatics. The Tenon’s tissue and episclera are 
highly vascular with a network of capillary plexi. The reported rate of removal of drugs is 
between 5 and 80% (Edelhauser et al. 2010). This has implications not just for reaching the 
therapeutic concentration but also for preventing systemic toxicity. 
Molecules that evade clearance by the subconjunctival circulation reach the sclera, 
the outer coating of the globe. The sclera is continuous with the cornea at the limbus and 
has a larger surface area. The sclera is hydrated, mainly composed of collagen fibres and 
proteoglycans embedded in an ECM, but with few protein binding sites. Its permeability is 
comparable to the corneal stroma, and aqueous intercellular media carry molecules through 
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pores between the collagen fibres. Molecular radius appears to play a bigger role in 
determining drug permeability than lipophilicity (Prausnitz & Noonan 1998), and molecules of 
linear shape, for example dextrans, are less able to permeate than globular proteins 
(Geroski & Edelhauser 2001). Electrical charge also contributes to permeation. Positively 
charged molecules penetrate the sclera poorly, believed to be due to binding to the 
negatively charged proteoglycan matrix (Kim et al. 2007) .  
The choroid is below the sclera, and is a vascular network whose high flow rate 
results in considerable drug loss. The main function of the choroid is to supply the retina with 
nutrients and oxygen. Due to the retina being the most metabolically active tissue in the 
body (per unit mass), the choroid has a correspondingly high blood flow through it, again 
being the highest (per unit mass) in the body (Scheinman et al. 2011). The choroid contains 
an outer layer of large vessels, a middle layer of small vessels and an innermost capillary 
layer, the choriocapillaris. The choriocapillaris is fenestrated, which enhances metabolic 
exchange, but this highly dynamic equilibrium contributes to drug loss too.  
The retinal pigment epithelium (RPE) is a single layered structure that acts as the 
metabolic interface between the photoreceptors and choroid. It forms the outer BRB, with 
tight junctions between cells preventing the passage of large molecules and cells across it. 
The inner BRB is formed by the endothelium of retinal arterioles, which are also linked with 
tight junctions. Both the choroid and the RPE are pigmented and rich in melanin. Melanin 
binds to free radicals and other molecules by electrostatic and Van der Waals forces, or 
simple charge transfer (Larsson 1993). Melanin bound drug can form a reservoir that can 
gradually release to the surrounding cells and as a result, prolong drug release (Urtti 2006; 
Gaudana, Ananthula, Parenky & Ashim K. Mitra 2010; Manzanares et al. 2016). The binding 
of drugs to melanin is especially important in transscleral drug delivery. The unbound drug is 
the driving force in drug permeation and the bound drug acts as a reservoir (Ranta & Urtti 
2006). Significant retention of lipophilic compounds occurs within the Bruch’s membrane and 
the choroid presumably due to the high levels of melanin (Cheruvu & Kompella 2006). 
However, the choroid-RPE is even more impermeable to hydrophilic molecules, being up to 
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20 times less permeable to hydrophilic beta-blockers than lipophilic ones (Pitkanen 2005). 
There do appear to be regional and species specific differences within the choroid-RPE 
(Durairaj et al. 2012). The peripheral choroid-RPE contains more melanin than central 
choroid-RPE. In humans, unlike monkeys or rabbits, there is also evidence that the sclera 
may contain more melanin than the central choroid-RPE (Durairaj et al. 2012). These 
differences should be considered when using animal models for drug development as it can 
contribute varying pharmacokinetic and clearance profiles. 
Injection routes of administration  
Sub-Tenon injections 
Sub Tenon’s injection of certain drugs has been shown to be efficacious for posterior 
segment disease. Inflammation is a key part of the pathophysiology of macular oedema 
following cataract surgery (Irvine Gass syndrome), diabetic macular oedema, and posterior 
uveitis. The steroid triamcinolone acetonide (TA) has been used as treatment for these 
conditions with variable success. Most commonly it is administered as an IVT injection, but is 
associated with the additional specific complications of cataract and raised IOP. Sub-
Tenon’s administration may carry a lower risk of complications. No difference in visual acuity 
outcomes for uveitic macular oedema was noted between IVT and sub-Tenon administration 
of TA (Choudhry & Ghosh 2007). There is also evidence that sub-Tenon injection leads to a 
significant increase of steroid in vitreous levels. Patients that received sub-Tenon’s TA (40 
mg/mL) preoperatively before macular hole surgery were found to have vitreous levels 
maintained between 17 and 31 ng/mL for 2 months (Kovacs et al. 2012). Systemic toxicity 
may be an issue with sub-Tenon’s steroid injection. In this study plasma cortisol levels were 
also altered, indicating implications for patients with poor glucose control such as diabetics. 
Other transscleral delivery systems are at different stages of development. Implants 
have been designed with an impervious casing for sub-Tenon’s placement and openings 
directed towards the sclera (Pontes De Carvalho 2006). Using this method of delivery of the 
This article is protected by copyright. All rights reserved. 
chemotherapeutic agents carboplatin and topotecan clinical trials evaluating efficacy are 
currently underway for the treatment of retinoblastoma.  
Intravitreal (IVT) injections  
The delivery of most treatments for the posterior segment must be by IVT injection due to 
transscleral barriers. This is particularly pertinent for the delivery of large molecules such as 
anti-VEGF antibodies, although periocular delivery and even topical delivery continues to be 
explored (Chen et al. 2011). Due to the invasive nature and the associated risks of IVT 
injections, there is much effort to develop longer lasting therapies, which require a reduced 
dosing frequency. 
Understanding the pharmacokinetics of drugs in the vitreous of humans is a 
significant challenge. The vitreous of humans is of a different consistency to other animals. It 
also undergoes considerable changes with age (Sebag 1989). As people grow older the 
vitreous loses viscosity, with lakes of fluid appearing within it (Bishop 2000). Collagen fibril 
links break down in some parts of the vitreous and fibrils aggregate in other parts (Bishop 
2000; P N Bishop et al. 2004).  At the weaker points the attachments can fall away and float 
around inside the eye. This lack of uniformity will affect drug distribution, but may 
preferentially result for example in anti-VEGF treatment being located over the macula.  
The administration of humanised protein therapeutics (e.g. antibodies) intravitreally 
results in proteins diffusing more slowly in the vitreous than low molecular weight (MW) 
molecules.  Therapeutic protein clearance times tend to be much longer than that of low MW 
molecules (days compared to hours) (Hayreh 1966; Cunha-Vaz 1997; Thrimawithana et al. 
2011; Urtti 2006; Pitkanen 2005; Haghjou et al. 2013; Kwak & Amico 1992; Laude et al. 
2010). An issue with therapeutic proteins is that the use of animals to evaluate 
pharmacokinetics will result in the development anti-drug antibodies (ADAs). The presence 
of ADAs will result in rapid clearance of the candidate protein and can also cause acute 
hypersensitivity or infusion reactions. ADAs can also bind to the active region of the 
therapeutic protein such as the receptor-binding site to neutralise the drug. Efficacy can 
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therefore be difficult to determine. ADAs unpredictively change drug pharmacokinetic 
properties, biological effects and toxicity profile (Vugmeyster et al. 2012; Brinks et al. 2011; 
Tamilvanan et al. 2010; Wang et al. 2012; Brinch et al. 2009). ADAs are an intractable 
problem in the development of protein therapeutics, especially new formulations with 
prolonged duration of action that are being developed.  
Another factor whose contribution to drug distribution in the vitreous is difficult to 
quantify are eye movements. Saccades can result in sudden globe rotations of up to nine 
hundred degrees per second, approximately half the speed of an old washing machine on a 
spin cycle. These abrupt changes shake up the vitreous, and affect drug distribution. As the 
posterior segment is not a perfect sphere, with the lens causing a concave indentation, 
vortices are created with eye movements (Stocchino et al. 2007; Repetto et al. 2010).  
Estimation of drug distribution and clearance is therefore difficult new in vitro models 
have recently been reported (Awwad et al. 2013; Awwad et al. 2015; Awwad et al. 2017; 
Repetto et al. 2005; Fogli et al. 2014; Patel et al. 2015). Therapeutic proteins do not readily 
permeate the retina and thus clear via aqueous outflow through the anterior chamber into 
the conjunctiva. A two-compartment model of the eye that mimics aqueous outflow mimics 
the human clearance times of therapeutic proteins (Awwad et al. 2015).  
Some controversy exists in the treatment regimen frequency for certain pathologies. 
Exudative macular degeneration is a pathology that involves blood vessel growth and 
leakage from the choroid underneath the macula (CNV). Disruption of the retinal layers 
results in loss of visual function. A major factor to new blood vessel growth is VEGF that is 
released in association with oxidative stress. Anti-VEGF antibodies have revolutionised 
treatment outcomes, with patients showing stabilisation or improvement of vision together 
with leakage regression. What remains unclear is the frequency and time span of drug 
administration. Both the ANCHOR and MARINA trials examined visual outcomes after 
monthly dosing of ranibizumab, a humanised monoclonal antibody fragment (Fab) (Brown et 
al. 2006; Rosenfeld et al. 2006). Other trials such as the PRONTO or SUSTAIN trial have 
shown significant benefit from monthly injections of ranibizumab for 3 months only, then 
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injections as required (Holz et al. 2011; Lalwani et al. 2009). Comparative data between 
injections as required and monthly injections found little difference in outcome at one year in 
the CATT trial.  The CATT and IVAN trials also compared the use of ranibizumab and 
bevacizumab, which is used unlicensed. Bevacizumab is a full IgG1 antibody registered for 
systemic use in cancer, but its use has been shown by the CATT (CATT Research Group et 
al. 2011) and IVAN (Chakravarthy et al. 2012) trials to be broadly similar to that of 
ranibizumab. Issues arise because bevacizumab has not been formulated for ocular use (Ng 
et al. 2012; L. Liu et al. 2011; Palmer et al. 2013). Presentation of bevacizumab is in a vial 
containing 25 mg/mL of antibody and the dose was established simply by what was in a 50 
mL injection.  However costs are dramatically reduced compared to ranibizumab, so 
bevacizumab is also widely used to treat conditions related to vascularistion (e.g. AMD).   
Intravitreal (IVT) implants  
A strategy to prolong drug action that has long been used clinically for low MW molecules is 
the IVT injection of a drug suspension of a poorly soluble drug. Although not yet possible 
with therapeutic proteins, this approach works with poorly soluble steroids.  TA, as discussed 
earlier, consists of a suspension of steroid particles. An injection of 4.0 mg of TA has been 
shown to maintain elevated levels of steroid up to 3 months in non-vitrectomised eyes 
(Mason et al. 2004). The 4.0 mg dose is too large of a mass to dissolve in the eye, so TA 
dissolution occurs slowly over time with aqueous flow (Jermak et al. 2007; Zacharias et al. 
2013; Yilmaz et al. 2011).  
A growing field of research is the use of implants for the treatment of posterior 
segment disease (Figure 1, Table 2). These allow sustained release of drug negating the 
need for multiple injections. Taking advantage of the privileged immune state of the inside 
the eye, many implants have been used successfully without inciting the significant 
inflammatory reaction that would normally be found with implants used elsewhere in the 
body (Ratner 2002). Chronic diseases or those with a relapsing remitting course are 
particularly appropriate for sustained release implant therapy.  The implants may be 
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formulated from biodegradable or non-biodegradable substances (Choonara et al. 2010; 
Thrimawithana et al. 2011; Thakur et al. 2014; Lee et al. 2010; Kang-Mieler et al. 2014; 
Christoforidis et al. 2012; Gilger et al. 2013; Cima et al. 2014; Bisht et al. 2017; Prata et al. 
2017). 
In immunocompromised patients, such as those with leukaemia or acquired immune 
deficiency syndrome (AIDS) the opportunistic infection CMV can cause retinal destruction 
(Pollard 1980). Patients may remain asymptomatic until advanced stages of retinal necrosis 
and haemorrhage. The advent of highly active antiretroviral therapy (HAART) has reduced 
the incidence of patients developing CMV retinitis, however individuals with specific immune 
deficiency to CMV may still develop retinitis. Effective treatment of CMV retinitis not only 
reduces the risk of vision loss, but also is associated with a decrease in mortality. Standard 
therapy may include ganciclovir (Martin et al. 1999; Pollard 1996), foscarnet (Berthe et al. 
1994; López-Cortés et al. 2001), and cidofovir (Biron 2006; Ljungman et al. 2001).  
The ganciclovir slow release implant (Vitrasert) was one of the first approved 
implants for IVT application (Sepahvandi et al. 2016). It releases ganciclovir at 1 mcg/hour 
from a PVA/EVA polymer based system. In a clinical trial it was found to be twice as 
effective in slowing retinitis progression than treatment with intravenous ganciclovir (Musch 
et al. 1997). One of the pitfalls of implant treatment to one eye only, however, is that is that 
the other eye is not protected, and in the implant treated group of patients the time to second 
eye involvement was significantly shorter. Combination therapy with both implant and oral 
valganciclovir (oral version of ganciclovir) is now advocated for sight threatening retinitis 
(Jabs 2008). Controversy exists as to whether implants should be removed from the eye 
after drug has been released, as its removal is associated with a risk of retinal detachment, 
haemorrhage and infection.  
Treatment of macular oedema has also been successfully achieved with steroid 
implants. Macular oedema results from the leakage of fluid from vessels within the retina, 
which disrupts the retinal architecture, and causes vision loss. It is seen in association with 
uveitis, RVO and diabetic maculopathy. IVT injection of the steroid TA has shown benefit in 
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reducing oedema, however recurrence is a common feature of all diseases. Work on a 
dexamethasone pellet coated in PVA/EVA showed promise using a uveitic model of rabbits 
(Cheng et al. 1995). The Ozurdex® implant has recently been approved by the FDA for the 
treatment of macular oedema in association with non-infectious uveitis and RVO (Mehta et 
al. 2015; Barar et al. 2016). It consists of 0.7 mg of dexamethasone integrated into a 
poly(lactic–co-glycolic acid) (PLGA) polymer. Pharmacokinetic studies revealed that steroid 
continues to be released into the vitreous over a period of 4 months (Chang-Lin & Attar 
2011). The polymer has the added advantage of being biodegradable, requiring no surgical 
removal. Other implants are at different stages of development (Table 2). 
Future directions 
Prolonging the duration of drug action to targets while maintaining drug stability and 
specificity are key goals of current research. Novel ways of solubilising drugs by conjugation 
with carriers, gene therapy and implants that are refillable or able to be directed remotely to 
the area of treatment are concepts in the process of development. 
Dendrimers 
Nanotechnology has been used to increase the drug residence time. Dendrimers are nano-
sized, three-dimensional structures with a central core from which polymeric branches 
emerge (Patri et al. 2002). The hydrophobic drug is encapsulated in the internal cavity or 
complexed to the dendrimer. Its tree-like structure consists of a high surface density of 
functional groups, which make it possible to attach a wide variety of conjugates. Dendrimers 
can aid in controlled drug release due to their small size, high chemical versatility, drug 
loading capacity and ease in preparation (Rodríguez Villanueva et al. 2016; Yavuz et al. 
2015). The poly amidoamine (PAMAM) dendrimers include functional carboxylic, hydroxyl 
and amine groups, and these increases with generation number.  
Dendrimer drug complexes have shown potential as an application for prolonging 
treatment of CNV. A dendrimer complex of anti-VEGF antisense oligonucleotide was found 
to inhibit CNV in a laser induced rodent model when injected to the vitreous. The effective 
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lifespan of the dendrimer bound oligonucleotide was reported to be between 4-6 months, 
with effective protection against nucleases whilst also facilitating its delivery to the target site 
(Marano et al. 2005).  
In a rabbit scarring model after glaucoma filtration surgery (GFS), dendrimer 
conjugates (dendrimer-glucosamine as an immunomodulator and dendrimer glucosamine 6- 
sulphate as an anti-angiogenic molecule) were found to be efficacious as an anti-scarring 
agent. Histopathological examination of the eyes showed minimal scar tissue formation and 
no inflammatory or neoangiogenic response, and success of GFS was promoted from 30 to 
80% (Shaunak et al. 2004).  
PAMAM dendrimers have also been found to be compatible with topical ocular 
dosage form formulations in terms of physicochemical properties (pH, osmolality and 
viscosity) (Vandamme & Brobeck 2005). Topical formulations of drugs such as pilocarpine 
nitrate (Vandamme & Brobeck 2005), carteolol (Spataro et al. 2010) and dexamethasone 
(Yavuz et al. 2015) have been reported. Puerarin-PAMAM dendrimer complex increased the 
corneal residence time of the drug thereby improving the efficacy and decreasing the 
frequency of dosing (Yao et al. 2010). This system also improved the availability of puerarin 
and delayed the half-life of drug in aqueous humor of rabbits from 0.48 to 1.30 hours (Wang 
et al. 2011).  
Hydrogels 
Hydrogels have received considerable interest in recent years due to their ability to prolong 
efficacy whilst being biocompatible and biodegradable. Hydrogels are an alternative to 
particulate associated formulations and have been used for the delivery of large MW 
molecules (Mitragotri et al. 2014). They are polymeric materials that do not dissolve in water 
under physiological conditions and swell considerably in aqueous medium. Many hydrogel 
systems that have been described do not require organic solvents during preparation (Shi et 
al. 2013; Stile et al. 1999; Vermonden et al. 2012). Hydrogels are networks of polymer main 
chains covalently linked together. This is known as crosslinking and sometimes the polymer 
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crosslinks can be strong non-covalent interactions. The crosslinking of polymer chains 
prevents complete dissolution of the polymer in a good solvent. Hence, hydrogels made of 
hydrophilic polymers can imbibe water into their network structure and swell. The high water 
content property of hydrogels makes them biocompatible and is being examined in tissue 
regeneration application. However, the high water content of hydrogels is a challenge for 
developing extended drug release. Hydrogels can be made with polymers that can undergo 
a phase transition in response to different external conditions such as pH, temperature, 
electric currents and ionic strength (Simões et al. 2012). Such hydrogels can be made to 
‘collapse’ to entrap a drug after administration.  
One thermosensitive material that shows gel-sol transition is poly(N-
isopropylacrylamide) (pNIPAAM) (Yıldız et al. 2002; Silva & Oliveira 2007; Li et al. 2008; 
Klouda 2015; Drapala et al. 2011). It has been used in many drug delivery and tissue 
engineering studies (Li et al. 2008), with no signs of retinal toxicity (Turturro et al. 2011). 
PNIPAAM has a transition temperature of 32 °C and cross-linking the hydrogel with 
poly(ethylene glycol) diacrylate (PEGDA) improves drug release profile by forming 
homogenous pores (Zhang et al. 2009). This characteristic has been exploited to 
encapsulate and release protein for ocular delivery to the posterior segment.  
 
Reservoir type devices 
Another approach being explored recently is the use of refillable reservoir type devices. 
When the existing drug depletes, more drug can be refilled in the reservoir. An 
microelectromechanical system (MEMS) drug delivery device consisting of a pump, drug 
reservoir and transscleral cannula showed promise in ex-vivo porcine eyes (Li et al. 2008). 
Another MEMS device described in the literature has layers formed using lithography and 
master moulds made up of silicon wafers or acrylic. A hard-core base plate made up of 
polyetherether ketone is used to control the penetration depth of the needle, and prevent the 
puncture of the entire device with the force of needle. It is surgically implanted with the 
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reservoir placed beneath the conjunctiva, with the cannula inserted through the sclera and 
drug dispensing tip, terminating in either the anterior or posterior segment depending on the 
site of treatment required. When mechanically actuated by force applied by the patient’s 
finger, a pressure gradient arises and the drug flows into the transscleral cannula. The one-
way valve at the end of the cannula opens and results in release of a specific dose of the 
medication. This device was tested in vivo on rabbits using phenylephrine as a model drug 
(Lo et al. 2009). The Port Delivery System (PDS, ForSight VISION4, Inc.) is a refillable drug 
delivery device currently in phase 1 for preliminary safety for neovascular AMD 
(www.clinicaltrials.gov: NCT01186432) (Pearce et al. 2015). 
Selective IVT drug delivery using a microrobotic device is a novel invention. 
Controlled electromagnetically, it acts as an IVT implant with a drug reservoir (Weidle et al. 
2013). These microrobots can be placed in the lower vessel arcade without obstructing 
vision. Non-biodegradable, they are made biocompatible by coating with polypyrrole. It was 
demonstrated in vitro and ex vivo that the movement of this device could be wirelessly 
controlled in the vitreous. The group proposed an algorithm taking into account the complex 
optics of the eye that helps to localise the device based on 3-D structure and allows precise 
calculation of gradients and forces acting on the device.  
 
Stem cell technology 
Stem cells have been explored as a potential avenue for treatment of ocular diseases 
(Ramsden et al. 2013; Jeon & Oh 2015; Rao et al. 2017). Stem cells have the ability to grow 
into many different cell types and other kinds of cells can arise from differentiation (Vellonen 
et al. 2014). Stem cells are critical to the renewal and repair of tissue in the body. Pluripotent 
stem cells (embryonic stem cells, ESCs and induced pluripotent stem cells, iPSCs) are a rich 
source for the regeneration of damaged organs and tissues (Higuchi et al. 2017). Methods 
have been reported for the differentiation of human pluripotent stem cells (hPSCs) (Rezania 
et al. 2014; Burridge et al. 2014; Pagliuca et al. 2014; Gao et al. 2013; Bao et al. 2015).   A 
This article is protected by copyright. All rights reserved. 
key challenge for the clinical use of stem cells is to optimise cell placement and the local 
host environment so that cell survival, differentiation and integration leads to the long-term 
restoration of tissue function (Limb & Daniels 2008). One of the major barriers to successful 
stem cell implantation and integration is to mediate the local inflammatory and fibrotic 
responses to the transplantation. 
Stem cell treatments for corneal injuries are available clinically (Daniels et al. 2007; 
Daniels et al. 2006). Recent progress in retinal stem cell research has been reported for the 
treatment of dry AMD. Though no treatment has been reported for the management of dry 
AMD, vitamins and anti-oxidants have been used to slow its progression. Stem cells could 
possibly help treat severe retinal degeneration involved in the condition to restore sight 
(Jeon & Oh 2015). Several trials are currently underway to treat AMD and retinitis 
pigmentosa using human embryonic, foetal and umbilical cord tissue-derived stem cells and 
bone marrow derived stem cells (Ramsden et al. 2013). 
Though stem cell transplantation for retinal diseases has made considerable 
progress in the last decade, many issues however still need to be resolved before stem cell 
therapies can be routinely used in the clinic (Rao et al. 2017). Biological risk and technical 
difficulties associated with differentiation and culture procedures still need to be resolved 
(Jeon & Oh 2015). As understanding of retinal regeneration phenomena increases, there will 
be increased possibilities for cell therapies to regenerate retinal ocular tissues. 
 
Gene therapy 
Gene products have been reported to slow or prevent neovascularisation (Garoon & Stout 
2016). Gene therapies (Rowe-Rendleman et al. 2014) require direct cellular delivery (del 
Amo et al. 2017) using a carrier system (Schön et al. 2015) where a key challenge is to 
release the gene drug from the carrier within the cell (Karimi et al. 2016), often further 
requiring the gene drug entering the nucleus. Vector loaded suspensions can be 
administered via a sub-retinal injection by pars plana vitrectomy with retinotomy and injection 
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into the subretinal space with a 41-gauge cannula (Garoon & Stout 2016). It is necessary for 
gene therapy that there be no toxicity or immunogenicity after the delivery of highly efficient 
genes to specific targeted cells (Bloquel et al. 2006). Both viral and non-viral vectors are 
available. Examples of viral vectors include adenoviruses, adeno-associated-virus (AAV), 
retroviruses and lentivirus vectors (Borrás 2003; Chaum & Hatton 2002; Mohan et al. 2005; 
Garoon & Stout 2016). Adenoviruses are the most commonly used vector targeted for a 
variety of chronic ocular diseases.  Requiring sub-retinal injection, there are some AAV-
based systems in clinical trials (Bainbridge et al. 2015; Weleber et al. 2016).  The 
administration of adenoviruses allows for stable, long-term transgene expression in 
photoreceptors, RPE cells, ganglion cells and Müller cells (M. M. Liu et al. 2011). Viral 
vectors have been reported to display potential risks, such as mutagenesis and 
immunogenicity; resulting in hindrance to future development of these systems (Bloquel et 
al. 2006). An alternative solution are non-viral vectors, which display no toxicity and do not 
induce significant ocular inflammation (Bloquel et al. 2006). Reviews dedicated to gene 
therapy for ocular drug delivery can be found elsewhere (Bloquel et al. 2006; Garoon & Stout 
2016; Oliveira et al. 2017; Boye et al. 2013; Bainbridge et al. 2006). 
 
Neuroprotective agents 
Ciliary neurotrophic factor (CNTF) is a cytokine belonging to the interleukin-6 (IL-6) family. 
CNTF promotes neurotransmitter synthesis, neurite outgrowth and photoreceptor survival 
(M. M. Liu et al. 2011). CNTF has been shown to be protective against ganglion cell death in 
models of oxidative stress and experimental glaucoma (Lipinski et al. 2015). Studies with 
recombinant adeno-associated virus (rAAV)-mediated gene therapy showed sustained 
expression of CNTF with the protection of photoreceptors (Bok et al. 2002; Liang et al. 2001; 
Schlichtenbrede et al. 2003). NT-501 (Neurotech Pharmaceuticals) is an implantable cell 
technology comprising of encapsulated human RPE cells (ARPE-19) genetically modified to 
secrete CNTF over an extended period of time for the treatment of glaucoma and retinitis 
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pigmentosa. In a clinical trial NT-501 was found to reduce photoreceptor degradation in 
patients with retinitis pigmentosa with improvement in objective visual acuity (Sieving et al. 
2006). The implant consists of a scaffold of six strands of polyethylene terephthalate (PET) 
yarn and is sutured onto the sclera through a titanium loop (Thrimawithana et al. 2011). A 
semipermeable membrane allows the inward and outward diffusion of CNTF and prevents 
the attack of the host immune system. NT-501 represents a unique platform for the delivery 
of protein therapeutics (Sieving et al. 2006). NT-501 has completed phase II clinical trial for 
patients with atrophic macular degeneration (NCT00447954) and the implant was reported 
to be well tolerated (Girmens et al. 2012). 
 
Conclusions 
The eye is unique as a therapeutic target in the body. Whilst exhibiting a vast range of 
pathology, both local and systemic, the superficial nature enables effective local therapy. 
The privileged state of immune system inside the eye means there is greater tolerance of 
non-host materials, although with a significant infection risk each time the walls are 
breached. Ocular therapeutic development is therefore geared towards improving 
bioavailability of topical and periocular treatments, while efficacious sustained release 
implants are the cornerstone of development for therapies of the posterior segment. 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Southan et al. 2016), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al. 2015). 
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Table 1: U.S. Food and Drug Administration (FDA) approved and current clinical trial drugs for treatment of anterior segment diseases 
 
Name and company Drug delivery 
platform 
Drug and excipients Indications Status 
Acuvail™ (Allergan) Eye drops Solution of ketorolac tromethamine (0.45%) in 
carboxymethylcellulose (pH 6.8) 
Reduction of pain and inflammation 
post cataract surgery 
Approved 
Azasite
®
 (InSite 
Vision) 
Eye drops Solution of azithromycin (1.0%) in polycarbophil 
(Durasite
®
) 
Bacterial conjunctivitis Approved 
Azasite Plus™ 
(InSite Vision) 
Eye drops Solution of azithromycin (1.0%)/dexamethasone (0.1%) 
(ISV-502) in Durasite
®
 
Blepharoconjunctivitis  Phase III 
completed 
Bromsite™ (InSite 
Vision) 
Eye drops Solution of bromfenac sodium (0.075%) Reduction of pain and inflammation 
post cataract surgery 
Approved 
Betoptic-S™ (Alcon) Eye drops Suspension of betaxolol (0.25%) in polystyrene-
divinylbenzene) sulfonic acid, carbomer and BAC (0.01%) 
Open angle glaucoma Approved 
Cationorm
®
 (Santen 
Pharma) 
Eye drops Cationic emulsion  Dry eye Approved 
DexaSite™ (InSite 
Vision) 
Eye drops Solution of dexamethasone (0.1%) (ISV-305) in Durasite
®
 Reduction of pain and inflammation 
post cataract surgery; and non-
bacterial blepharitis 
Phase III 
Durezol™ (Alcon) Eye drops Emulsion of difluprednate (0.05%) in castor oil, glycerine, 
boric acid, polysorbate 80 and sorbic acid (0.1%) 
Anterior uveitis Approved 
 
EGP-437 (Eyegate
 
Pharma) 
Iontophoresis Solution of dexamethasone phosphate in EyeGate
®
 II 
Drug Delivery System (EGDS) 
Anterior uveitis Phase III 
Indocollirio
® 
(Bausch 
& Lomb) 
Eye drops Suspension of indomethacin (0.1%) and hydroxypropyl-b-
cyclodextrin (IND-CD) 
Mydriasis during cataract surgery or 
conjunctivitis 
Approved 
Lacrisert
®
 (Aton 
Pharma) 
Ocular insert Sterile, rod-shaped HPMC insert Dry eye Approved 
Lumigan
®
 (Allergan) Eye drops Solution of bimatoprost (0.03%) in BAC (0.005%) Glaucoma Approved 
Mydriasert (Thea 
Pharma) 
Ocular insert Tropricamide (0.28 mg) and phenylephrine hydrochloride 
(5.4 mg) in ammoniomethacrylate copolymer, glycerol and 
ethylcellulose 
Induced pre-operative mydriasis Approved 
Ocusert
®
 (Alza) Ocular insert Pilocarpine with EVA and alginic acid Glaucoma Approved 
Prolensa™ (Bausch 
& Lomb) 
Eye drops Solution of bromfenac (0.07%) Postoperative inflammation Approved 
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Propine™ (Allergan) Eye drops Solution of dipivefrin-HCl (0.1%) with BAC (0.02%) IOP control in open angle glaucoma Approved 
Restasis™ (Allergan) Eye drops Cationic emulsion of cyclosporine (0.05%) in castor oil, 
glycerine, polysorbate 80 and carbomer 
Dry eye Approved 
TobraDex
®
 (Alcon) Eye drops Suspension of tobramycin/dexamethasone in xanthan 
gum 
Blepharitis Approved 
Timoptic-XE™ (Aton 
Pharma) 
Eye drops In situ gel solution of timolol maleate (0.25 or 0.5%) in 
gellan gum, mannitol, tromethamine and BAC (0.012%) 
Glaucoma Approved 
Travatan™ (Alcon) Eye drops Solution of travaprost (0.004%) in BAC (0.015%) Glaucoma Approved 
Xalatan™ (Pfizer) Eye drops Solution of latanoprost (0.005%) in BAC (0.015%) Glaucoma Approved 
Zirgan™ (Bausch & 
Lomb) 
Ophthalmic gel Ophthalmic gel with ganciclovir (0.15%) with carbopol and 
BAC (0.0075%) 
Acute herpetic keratitis Approved 
 
Abbreviations: BAC: benzalkonim chloride, HPMC: hydroxypropylmethylcellulose. Note: All drug therapies mentioned above was also cross-checked with 
www.clinicaltrials.gov.uk and its official company site 
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Table 2: U.S. Food and Drug Administration (FDA) approved and current clinical trial drugs for treatment of posterior segment diseases 
 
Name and company Drug delivery platform Drug and excipients Indications and ongoining 
trials 
Status 
Brimonidine (Allergan) IVT implant Brimonidine (0.4 mg) with PLGA Dry AMD with GA Phase II 
Cortiject
®
/NOVA63035 
(Novagali Pharma) 
IVT Dexamethasone emulsion (preservative 
and solvent-free) 
DME  Phase I/II 
Durasert
TM
 (pSivida Corp) IVT implant Latanoprost with EVA/PVA Ocular hypertension and 
glaucoma 
Phase I/II 
I-vation
®
 (Surmodics Inc) Reservoir IVT implant TA (0.925 mg) with PMMA/EVA DME Phase IIb 
IBI-20089 (Icon Biosciences Inc) IVT TA (6.0 mg or 13.8 mg) and benzyl 
benzoate with lucentis (0.5 mg) 
AMD 
CNV 
Phase I 
Phase II 
Iluvien
TM
 (Alimera Sciences, 
Inc.) 
25-gauge IVT implant FA (0.19 mg) with polyimide/PVA DME 
AMD with GA 
Posterior uveitis 
Approved 
Phase II 
Phase III 
NT-501/Renexus (Neurotech 
Pharma) 
IVT implant CNTF with PET and ARPE-19 cells Glaucoma 
RP  
Phase I 
NT-503 (Neurotech Pharma) IVT implant 
IVT injection 
Anti-VEGF receptor protein Recurrent CNV with wet 
AMD 
Phase I 
Phase II 
NT-506 (Neurotech Pharma) IVT implant Anti-PDGF/Anti-VEGF Wet AMD Preclinical 
Ozurdex
®
 (Allergan) IVT implant Dexamethasone (0.7 mg) with PLGA DME, CRVO,  
uveitis 
Approved 
Posurdex (Allergan) IVT implant Dexamethasone Posterior uveitis 
DME  
Phase III 
Phase III 
Retisert
® 
(Bausch & Lomb) Reservoir IVT implant FA (0.59 mg) with silicone/PVA Non-infectious uveitis Approved 
Vitrasert
®
 (pSivida Corp) Reservoir IVT implant Ganciclovir with  EVA/ PVA CMV retinitis Approved 
 
Abbrevitations: AMD: age-related macular degeneration; BRVO: branch retinal vein occlusion; CMV: cytomegalovirus; CNTF: ciliary neutrophic factor; CRVO: central retinal 
vein occlusion; EVA: ethylene-vinyl acetate; FA: fluocinolone acetonide; GA: geographic atrophy; IVT: Intravitreal; PDGF: platelet-derived growth factor; PET: polyethylene 
terephthalate; PLGA: poly(lactide-co-glycolide); PMMA: poly(methyl methacrylate); PVA: poly(vinyl alcohol); RP: retinitis pigmentosa; TA: Triamcinolone acetonide, VEGF: 
vascular endothelial growth factor. Note: All drug therapies mentioned above was also cross-checked with www.clinicaltrials.gov.uk and its official company site 
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Figure 1: Some of the drug delivery technologies indicated for treatment of posterior 
segment diseases 
 
 
